文献速递乳腺癌放疗放疗物理与技术

新型深吸气屏气装置在左侧乳腺癌放疗中的2期临床试验验证

A Novel Device for Deep-Inspiration Breath Hold (DIBH): Results from a Single-Institution Phase 2 Clinical Trial for Patients with Left-Sided Breast Cancer.
PubMed 文献 · Pract Radiat Oncol · 2020-02-14

该单中心2期临床试验评估了一种新型深吸气屏气(DIBH)装置引导左侧乳腺癌放疗的性能与剂量学获益。DIBH下心脏、左前降支冠状动脉及同侧肺剂量参数显著降低,且靶区覆盖未受损。

要点

  • 新型DIBH装置提供机械参考及声光反馈,稳定性与重复性最大群体值分别为1.7 mm和3.3 mm。
  • 重现性均值1.7 mm,群体系统误差和随机误差分别为0.3 mm和0.9 mm,可靠性98.9%。
  • DIBH下心脏、左前降支冠状动脉及同侧肺剂量显著降低,计划靶区覆盖未丢失。

核心结论

  • 该装置在2期临床试验中验证成功,能提供可靠、稳定、可重复且重现性好的DIBH乳腺癌放疗,并具有剂量学获益。

研究设计与样本

  • 装置利用外部机械参考引导患者达到目标吸气水平,并分别向患者和放疗技师提供声学与视觉反馈。
  • 以胸廓振幅作为吸气水平的替代指标,分析DIBH的稳定性、重复性、重现性和可靠性,并比较自由呼吸与DIBH下心脏、左前降支冠状动脉、同侧肺、对侧乳腺及靶区覆盖的剂量学参数。

主要发现

  • 稳定性和重复性的最大群体值分别为1.7 mm和3.3 mm。
  • 重现性均值为1.7 mm,群体系统误差和随机误差分别为0.3 mm和0.9 mm。
  • 可靠性为98.9%。
  • DIBH下心脏、左前降支冠状动脉和同侧肺的剂量学参数出现统计学显著降低,且未丢失计划靶区的剂量覆盖。

临床怎么用

  • 该装置可用于左侧乳腺癌DIBH放疗,以提升屏气引导的可靠性和重复性,并降低心脏、左前降支冠状动脉及同侧肺剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To validate a novel device developed at our institution for deep inspiration breath hold (DIBH) within a phase 2 clinical trial for left-sided breast cancer and to evaluate the dosimetric benefits of its use. METHODS AND MATERIALS: The device uses an external mechanical reference for guiding the patient to the desired breath level and gives acoustic and visual feedback to the patient and the radiation therapists, respectively. A phase 2 clinical trial was performed for its validation. The thoracic amplitude was used as a surrogate of the inspiration level. The stability, repeatability, reproducibility, and reliability of DIBH using the device were analyzed. The dosimetric parameters of the heart, the left anterior descending coronary artery, the ipsilateral lung, the contralateral breast, and the target coverage using free breathing and DIBH were compared. RESULTS: Thirty-eight patients were included in the analysis. The maximum population value of stability and repeatability were 1.7 mm and 3.3 mm, respectively. The reproducibility mean value was 1.7 mm, and population systematic and random errors were 0.3 mm and 0.9 mm, respectively. The reliability was 98.9%. Statistically significant dose reductions were found for the heart, the left anterior descending coronary artery, and the ipsilateral lung dosimetric parameters in DIBH, without losing dose coverage to the planning target volumes. CONCLUSIONS: The validation of the device within the phase 2 clinical trial demonstrates that it offers reliable, stable, repeatable, and reproducible breast cancer treatments in DIBH with its dosimetric benefits.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Romera-Martínez I, Muñoz-Montplet C, Jurado-Bruggeman D, et al. A Novel Device for Deep-Inspiration Breath Hold (DIBH): Results from a Single-Institution Phase 2 Clinical Trial for Patients with Left-Sided Breast Cancer. Pract Radiat Oncol. 2020. PMID: 32068155. doi:10.1016/j.prro.2020.02.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。